These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 18827821)

  • 1. Faecal tumour pyruvate kinase M2: not a good marker for the detection of colorectal adenomas.
    Shastri YM; Stein JM
    Br J Cancer; 2008 Oct; 99(8):1366; author reply 1367. PubMed ID: 18827821
    [No Abstract]   [Full Text] [Related]  

  • 2. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls.
    Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
    Anticancer Res; 2003; 23(2A):851-3. PubMed ID: 12820312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Faecal pyruvate kinase type M2--a valid screening parameter for colorectal cancer? Preliminary results from a multicenter comparative study].
    Naumann M; Schaum B; Oremek GM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein J
    Dtsch Med Wochenschr; 2004 Aug; 129(34-35):1806-7. PubMed ID: 15314744
    [No Abstract]   [Full Text] [Related]  

  • 4. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study.
    Haug U; Hundt S; Brenner H
    Br J Cancer; 2008 Jul; 99(1):133-5. PubMed ID: 18542075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data].
    Ewald N; Toepler M; Akinci A; Kloer HU; Bretzel RG; Hardt PD
    Z Gastroenterol; 2005 Dec; 43(12):1313-7. PubMed ID: 16315127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal pyruvate kinase-M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer.
    Ewald N; Schaller M; Bayer M; Akinci A; Bretzel RG; Kloer HU; Hardt PD
    Anticancer Res; 2007; 27(4A):1949-52. PubMed ID: 17649802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
    Kumar Y; Tapuria N; Kirmani N; Davidson BR
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of faecal M2-PK and FIT in a population-based bowel cancer screening cohort.
    Leen R; Seng-Lee C; Holleran G; O'Morain C; McNamara D
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):514-8. PubMed ID: 24699725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of different stool tests for the detection of cancer of the colon].
    Vogel T; Driemel C; Hauser A; Hansmann A; Lange S; Jonas M; Möslein G
    Dtsch Med Wochenschr; 2005 Apr; 130(14):872-7. PubMed ID: 15800820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal pyruvate kinase concentrations (ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening.
    Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
    Anticancer Res; 2003; 23(2A):855-7. PubMed ID: 12820313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
    Caviglia GP; Cabianca L; Fagoonee S; Gili FM
    Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis.
    Tonus C; Sellinger M; Koss K; Neupert G
    World J Gastroenterol; 2012 Aug; 18(30):4004-11. PubMed ID: 22912551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stool test for colorectal cancer screening--it's time to move!
    Loitsch SM; Shastri Y; Stein J
    Clin Lab; 2008; 54(11-12):473-84. PubMed ID: 19216253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy.
    Hardt PD; Ewald N
    Expert Rev Mol Diagn; 2008 Sep; 8(5):579-85. PubMed ID: 18785806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pilot study on M2-PK-- a new non-invasive parameter for early diagnosis of colorectal carcinoma].
    Ivanova A; Iarŭmov N; Toshev S; Adzharov D; Krŭstev Z; Angelov K; Sokolov M; Gribnev P
    Khirurgiia (Sofiia); 2007; (6):5-7. PubMed ID: 18622373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New faecal tests for colorectal cancer screening: is tumour pyruvate kinase M2 one of the options?
    Shastri YM; Stein JM
    Br J Cancer; 2007 Dec; 97(11):1595-6; author reply 1597. PubMed ID: 17955052
    [No Abstract]   [Full Text] [Related]  

  • 17. Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed.
    Rozen P; Levi Z; Hazazi R; Waked A; Vilkin A; Maoz E; Birkenfeld S; Leshno M; Niv Y
    Aliment Pharmacol Ther; 2009 Apr; 29(8):906-17. PubMed ID: 19183147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal Adnab-9 binding as a risk marker for colorectal neoplasia.
    Yuan M; Xhang X; Leu Y; Xu Y; Ullah N; Lawson M; Tobi M
    Cancer Lett; 2006 Apr; 235(1):48-52. PubMed ID: 15893419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).
    Hoff G; Grotmol T; Thiis-Evensen E; Bretthauer M; Gondal G; Vatn MH
    Gut; 2004 Sep; 53(9):1329-33. PubMed ID: 15306594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal tumor M2 pyruvate kinase is not a specific biomarker for colorectal cancer screening.
    Shastri YM; Stein J
    World J Gastroenterol; 2007 May; 13(19):2768-9. PubMed ID: 17569153
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.